Lineage Cell Therapeutics...

AMEX: LCTX · Real-Time Price · USD
1.19
0.17 (16.67%)
At close: Aug 15, 2025, 3:59 PM
1.20
0.84%
After-hours: Aug 15, 2025, 07:57 PM EDT

Lineage Cell Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-18.61M -21.49M -26.35M -43.27M
Depreciation & Amortization
609K 692K 727K 873K
Stock-Based Compensation
5.08M 4.64M 4.29M 3.52M
Other Working Capital
-7.19M -8.06M -12.94M 308K
Other Non-Cash Items
-1.4M 195K 3.73M 202K
Deferred Income Tax
n/a -1.8M n/a -6M
Change in Working Capital
-8.77M -10.8M 18.67M 21.11M
Operating Cash Flow
-23.09M -28.57M 1.06M -23.56M
Capital Expenditures
-565K -674K -413K -354K
Cash Acquisitions
n/a n/a 45.75M 10.09M
Purchase of Investments
-8.76M -16.4M -53.41M 6.02M
Sales Maturities Of Investments
7.02M 63.53M 7.67M -6.02M
Other Investing Acitivies
n/a n/a -45.75M 14K
Investing Cash Flow
-2.31M 46.45M -46.16M 9.74M
Debt Repayment
-54K -54K -32K -20K
Common Stock Repurchased
-23K -37K -17K -54K
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
58K -37K 1.53M 6.14M
Financial Cash Flow
35.86M 6.42M 1.63M 36.93M
Net Cash Flow
10.36M 24.06M -44.34M 23.09M
Free Cash Flow
-23.66M -29.24M 646K -23.91M